Potential anti-tumor effect of IFN-λ2 (IL-28A) against human lung cancer cells

Lung Cancer

Volumn 78, Issue 3, 2012, Pages 185-192

  Tezuka, Yasuhiro ^a,b   Endo, Shunsuke ^a   Matsui, Aya ^a,b   Sato, Atsuko ^a   Saito, Katsuyo ^b   Semba, Kentaro ^c   Takahashi, Masafumi ^a   Murakami, Takashi ^b  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b TAKASAKI UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^c WASEDA UNIVERSITY   (Japan)

Author keywords

Apoptosis; Bioluminescent imaging; EGFR mutation; IL 28A; Non small cell lung cancer; Type III interferon

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 7; EPIDERMAL GROWTH FACTOR RECEPTOR; INTERLEUKIN 28A; STAT1 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LUNG CANCER; MOUSE; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SHAPE; CELL SURVIVAL; HUMANS; INTERLEUKINS; LUNG NEOPLASMS; MICE; MICE, INBRED NOD; MICE, SCID; RECEPTORS, CYTOKINE; RECEPTORS, INTERLEUKIN; RECEPTORS, INTERLEUKIN-10; STAT1 TRANSCRIPTION FACTOR; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84868301688     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.09.005     Document Type: Article

References (31)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Detterbeck F.C., Boffa D.J., Tanoue L.T. The new lung cancer staging system. Chest 2009, 136:260-271.
3. Hutson T.E. Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence. Oncologist 2011, 16(Suppl. 2):14-22.
4. Garbe C., Eigentler T.K., Keilholz U., Hauschild A., Kirkwood J.M. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 2011, 16:5-24.
5. Rossi A., Garassino M.C., Cinquini M., Sburlati P., Di Maio M., Farina G., et al. Maintenance or consolidation therapy in small-cell lung cancer: a systematic review and meta-analysis. Lung Cancer 2010, 70:119-128.
6. Kelly K., Crowley J.J., Bunn P.A., Hazuka M.B., Beasley K., Upchurch C., et al. Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study. J Clin Oncol 1995, 13:2924-2930.
7. van Zandwijk N., Groen H.J., Postmus P.E., Burghouts J.T., ten Velde G.P., Ardizzoni A., et al. Role of recombinant interferon-gamma maintenance in responding patients with small cell lung cancer. A randomised phase III study of the EORTC Lung Cancer Cooperative Group. Eur J Cancer 1997, 33:1759-1766.
8. Sheppard P., Kindsvogel W., Xu W., Henderson K., Schlutsmeyer S., Whitmore T.E., et al. IL-28 IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2002, 4:63-68.
9. Donnelly R.P., Kotenko S.V. Interferon-lambda: a new addition to an old family. J Interferon Cytokine Res 2010, 30:555-564.
10. Muir A.J., Shiffman M.L., Zaman A., Yoffe B., de la Torre A., Flamm S., et al. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology 2010, 52:822-832.
11. Sato A., Ohtsuki M., Hata M., Kobayashi E., Murakami T. Antitumor activity of IFN-lambda in murine tumor models. J Immunol 2006, 176:7686-7694.
12. Li Q., Kawamura K., Ma G., Iwata F., Numasaki M., Suzuki N., et al. Interferon-λ induces G1 phase arrest or apoptosis in oesophageal carcinoma cells and produces anti-tumour effects in combination with anti-cancer agents. Eur J Cancer 2010, 46:180-190.
13. Zitzmann K., Brand S., Baehs S., Göke B., Meinecke J., Spöttl G., et al. Novel interferon-λs induce antiproliferative effects in neuroendocrine tumor cells. Biochem Biophys Res Commun 2006, 344:1334-1341.
14. Guenterberg K.D., Grignol V.P., Raig E.T., Zimmerer J.M., Chan A.N., Blaskovits F.M., et al. Interleukin-29 binds to melanoma cells inducing Jak-STAT signal transduction and apoptosis. Mol Cancer Ther 2010, 9:510-520.
15. Lasfar A., Lewis-Antes A., Smirnov S.V., Anantha S., Abushahba W., Tian B., et al. Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against B16 melanoma. Cancer Res 2006, 66:4468-4477.
16. Byers H.R., Etoh T., Doherty J.R., Sober A.J., Mihm M.C. Cell migration and actin organization in cultured human primary, recurrent cutaneous and metastatic melanoma Time-lapse and image analysis. Am J Pathol 1991, 139:423-435.
17. Murakami T., Toda S., Fujimoto M., Ohtsuki M., Byers H.R., Etoh T., et al. Constitutive activation of Wnt/beta-catenin signaling pathway in migration-active melanoma cells: role of LEF-1 in melanoma with increased metastatic potential. Biochem Biophys Res Commun 2001, 288:8-15.
18. Murakami T., Maki W., Cardones A.R., Fang H., Tun Kyi A., Nestle F.O., et al. Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res 2002, 62:7328-7334.
19. Murakami T., Cardones A.R., Finkelstein S.E., Restifo N.P., Klaunberg B.A., Nestle F.O., et al. Immune evasion by murine melanoma mediated through CC chemokine receptor-10. J Exp Med 2003, 198:1337-1347.
20. Kotenko S.V., Gallagher G., Baurin V.V., Lewis-Antes A., Shen M., Shah N.K., et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003, 4:69-77.
21. Dumoutier L., Tounsi A., Michiels T., Sommereyns C., Kotenko S.V., Renauld J.C. Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling. J Biol Chem 2004, 279:32269-32274.
22. Murakami T., Sato A., Chun N.A.L., Hara M., Naito Y., Kobayashi Y., et al. Transcriptional modulation using HDACi depsipeptide promotes immune cell-mediated tumor destruction of Murine B16 melanoma. J Invest Dermatol 2008, 128:1506-1516.
23. Yanagisawa S., Kadouchi I., Yokomori K., Hirose M., Hakozaki M., Hojo H., et al. Identification and metastatic potential of tumor-initiating cells in malignant rhabdoid tumor of the kidney. Clin Cancer Res 2009, 15:3014-3022.
24. Fujie H., Tanaka T., Tagawa M., Kaijun N., Watanabe M., Suzuki T., et al. Antitumor activity of type III interferon alone or in combination with type I interferon against human non-small cell lung cancer. Cancer Sci 2011, 102:1977-1990.
25. Sommereyns C., Paul S., Staeheli P., Michiels T. IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 2008, 4:e1000017.
26. de Mello R.A., Marques D.S., Medeiros R., Araujo A.M. Epidermal growth factor receptor and K-Ras in non-small cell lung cancer-molecular pathways involved and targeted therapies. World J Clin Oncol 2011, 2:367-376.
27. Sun S., Schiller J.H., Gazdar A.F. Lung cancer in never smokers-a different disease. Nat Rev Cancer 2007, 7:778-790.
28. Oliveras-Ferraros C., Vazquez-Martin A., Queralt B., Adrados M., Ortiz R., Cufi S., et al. Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux(R)) efficacy in KRAS wild-type squamous carcinomas: a pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models. Int J Oncol 2011, 39:1455-1479.
29. Hiramatsu M., Ninomiya H., Inamura K., Nomura K., Takeuchi K., Satoh Y., et al. Activation status of receptor tyrosine kinase downstream pathways in primary lung adenocarcinoma with reference of KRAS and EGFR mutations. Lung Cancer 2010, 70:94-102.
30. Hutson T.E., Figlin R.A., Kuhn J.G., Motzer R.J. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 2008, 13:1084-1096.
31. Pulverer J.E., Rand U., Lienenklaus S., Kugel D., Zietara N., Kochs G., et al. Temporal and spatial resolution of type I and III interferon responses in vivo. J Virol 2010, 84:8626-8638.